The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
June 6th 2025
New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
June 11th 2024At the ASHP Pharmacy Futures 2024 conference, Scott D. Nelson, PharmD, MS, ACHIP, FAMIA, discusses research showed that although AI models can significantly enhance diagnostic accuracy, they can also exacerbate existing disparities.
Read More
The Disruptive Impact of AI in Health Care
June 11th 2024Kenneth A. Richman, PhD, discusses the disruptive nature of artificial intelligence (AI) in health care, highlighting both its transformative potential and the ethical considerations of governability and sustainability in its implementation.
Read More
Pharmacy Focus: The Role of Pharmacists in Promoting Mental Health Care
June 7th 2024Molly McGraw, PharmD, BCPS, manager of clinical pharmacy at UPMC Health Plan and Kim Castelnovo, RPh, Pharmacy Manager at Community Care Behavioral Health Organization, talk about the importance of mental health care for patients.
Listen
Sustained MRD-Negativity With Sc Daratumumab in Newly Diagnosed Multiple Myeloma
June 4th 2024Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.
Watch
Enhanced Front Line Therapy for NDMM: Promising Results from the MajesTEC-7 Trial
June 4th 2024Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.
Watch
T-DXd New Standard of Care Following ET in HER2-Low, -Ultralow HR+ Metastatic Breast Cancer
June 3rd 2024Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).
Read More